The Extracellular Matrix Pharmacology Congress’ Post

How can you ensure the biomarkers you identify in early drug development translate into patients’ “real world” experience with their disease and treatment? A direct patient access approach to biospecimen procurement connects you with donors living with the specific disease states you are trying to treat. Enhance your biomarker analysis with specimens collected among Sanguine’s engaged, nationwide, and diverse Patient Community. Learn more about direct patient access... #biomarkers #patientjourney #drugdevelopment #SanguineDifferentiatorSeries#1

BIO-Europe really shows the diversity of approaches and indications that our industry is tackling. We met Stéphane Thiroloix, CEO of AlgoTx, at BIO-Europe who explained how the clinical stage II company applies the antidepressant Amitriptyline topically in a highly innovative approach to address chemotherapy-induced neuropathic pain (CINP) and for treatment of the rare disease erythromelalgia. If you couldn’t make it in person, you don’t have to miss out! Subscribe to our YouTube channel to learn more about highlights at the conference here 👉 https://bit.ly/MCS_YouTube #bioeurope #bioeurope2023 #BiotechInvestment #HealthcareInnovation

Complement analytes are known to vary widely across individuals both in the general population and across disease cohorts. Standard assays often require multiple dilutions to get in-range results. However Kypha assays have a broad dynamic range allowing for data capture without additional dilution steps. By eliminating these steps, we can simplify workflow and protect blinding in clinical trials. Find out more about how we develop complement assays at https://lnkd.in/ek9URAmc

Complement analytes are known to vary widely across individuals both in the general population and across disease cohorts. Standard assays often require multiple dilutions to get in-range results. However, Kypha assays have a broad dynamic range allowing for data capture without additional dilution steps. By eliminating these steps, we can simplify workflow and protect blinding in clinical trials. Find out more about how we develop complement assays at https://lnkd.in/ex69xauf

PA200-mediated degradation and the potential of PA200 as a therapeutic target in age-related disease, discussed in https://lnkd.in/gMaziv_W. Check out the interesting review article published in the special issue: Proteasomes and Cellular Senescence: An Age-Related Connection.

Fascinating study conducted by some of my seriously talented colleagues at BCG analyzing what it takes to make progress in a disease area (rather than looking at individual assets in a disease area as we often do in BioPharma). The analysis yielded an informative framework to identify diseases that do not have effective therapies but are ripe for success as well as key hurdles that need to be knocked down to make progress. The study suggests that developing sound translational models is a potential inefficiency in the current system that could be targeted to accelerate groundbreaking new therapies for patients. #BCG #Pharma #Innovation

Despite advances in science, many people living with systemic lupus erythematosus (SLE) still rely on high doses of oral corticosteroids for symptom control.     AstraZeneca remains dedicated to understanding the underlying drivers of immune-mediated diseases like SLE and eosinophilic granulomatosis with polyangiitis (EGPA). Join us at #ACR2023 to explore scientific advancements and their potential to transform patient outcomes: https://bit.ly/47bZiII

Take a look at the re-vamped fibrosis page on PhenoVista's website here! https://hubs.ly/Q02sYTf20 There's a general overview of our capabilities in this disease area and a case study of a completed client project. If you don't find what you're looking for or want to discuss challenges you're facing in fibrosis R&D, shoot let's chat!

Today, we end Rare Disease Day with a final Certara Talks episode dedicated to this important day. Our experts share what this day means to them and describe our commitment to accelerating medicines to patients globally. ▶️ Watch now: https://ow.ly/v7nS50QH9PR Ready to explore further? Dive into our white paper, "The Challenges and Opportunities of Rare Disease Drug Development," and uncover deeper insights into this critical field. https://ow.ly/EbaW50QH9PS #RareDiseaseDay #RegulatoryAffairs #CertaraTalks

We surveyed 100 professionals in the rare disease sector who collaborate with a contract research organization. The findings of this survey shed light on client requirements and challenges encountered during rare disease #clinicaltrials. Learn more about the respondents' therapeutic focus and gain insights into the #raredisease landscape. » https://bit.ly/3LdSzCQ #RareDiseaseDay